European Neuropsychopharmacology最新文献

英文中文

Biomarker innovations in precision psychiatry diagnostics and treatment strategies 精准精神病学诊断和治疗策略的生物标志物创新

IF 6.7 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2026-04-01 Epub Date: 2026-01-15 DOI: 10.1016/j.euroneuro.2026.112762

Martien J.H. Kas , Kim Q. Do , Michael S. Sand , Rouba Kozak , Elizabeth M. Tunbridge , Maria A. Oquendo , Carol Tamminga , Nikolaos Koutsouleris , Gitte Moos Knudsen , Brenda W.J.H. Penninx , Frank J. Padberg , Wayne C. Drevets , Peter Falkai , Derek L. Buhl , Andreas Reif

Precision psychiatry is an approach designed to improve diagnosis and treatment of mental disorders by leveraging biological insights and developing innovative, mechanism-based treatment strategies unconstrained by current diagnostic boundaries. At its core, precision psychiatry aims to pinpoint the underlying neurobiological mechanisms responsible for the emergence and persistence of symptoms of mental health conditions. This approach strives to create diagnostic tools and therapies targeting these mechanisms, potentially addressing previously resistant aspects of mental health conditions by providing more precise symptom management and possibly altering the disease trajectory. Although still in its nascent stages, the realization of precision psychiatry will result in a more refined and biology-informed diagnostic system for mental disorders, requiring significant adaptations for clinicians, industry, patients and regulators. Identifying, validating and applying both fluid and functional biomarkers are critical steps in the development, testing and application of new precision psychiatry diagnostics and treatments. As part of the 2025 Precision Psychiatry Roadmap initiative meeting in Frankfurt, experts came together to present and discuss the current status of biomarker identification and validation, patient subtyping, and targeted interventions for stratified patient groups. This report features lecture summaries, meeting outcomes, and recommendations from both online and in-person audiences. In general, the recommendations emphasize standardization, collaboration, clinical implementation, digital innovation, long-term planning, and, importantly, patient engagement, as key priorities for advancing precision psychiatry. Despite existing challenges, there is strong optimism for the future of precision psychiatry, with continuous efforts to refine diagnostic tools and treatment strategies.

精确精神病学是一种旨在通过利用生物学见解和开发创新的、基于机制的治疗策略来改善精神障碍的诊断和治疗的方法，不受当前诊断界限的限制。精确精神病学的核心是查明导致精神健康状况症状出现和持续的潜在神经生物学机制。这种方法致力于创造针对这些机制的诊断工具和治疗方法，通过提供更精确的症状管理和可能改变疾病轨迹，潜在地解决以前精神健康状况的抗性方面。尽管精确精神病学仍处于起步阶段，但它的实现将导致一个更精细、更了解生物学的精神障碍诊断系统，这需要临床医生、行业、患者和监管机构做出重大调整。识别、验证和应用流体和功能性生物标志物是开发、测试和应用新的精确精神病学诊断和治疗的关键步骤。作为2025年法兰克福精准精神病学路线图倡议会议的一部分，专家们齐聚一堂，介绍并讨论了生物标志物识别和验证、患者亚型和分层患者群体靶向干预的现状。本报告包括讲座总结、会议成果以及来自在线和现场听众的建议。总的来说，这些建议强调标准化、协作、临床实施、数字创新、长期规划，以及更重要的是，患者参与，作为推进精准精神病学的关键优先事项。尽管存在挑战，但随着不断完善诊断工具和治疗策略的努力，人们对精准精神病学的未来抱有强烈的乐观态度。

{"title":"Biomarker innovations in precision psychiatry diagnostics and treatment strategies","authors":"Martien J.H. Kas , Kim Q. Do , Michael S. Sand , Rouba Kozak , Elizabeth M. Tunbridge , Maria A. Oquendo , Carol Tamminga , Nikolaos Koutsouleris , Gitte Moos Knudsen , Brenda W.J.H. Penninx , Frank J. Padberg , Wayne C. Drevets , Peter Falkai , Derek L. Buhl , Andreas Reif","doi":"10.1016/j.euroneuro.2026.112762","DOIUrl":"10.1016/j.euroneuro.2026.112762","url":null,"abstract":"<div><div>Precision psychiatry is an approach designed to improve diagnosis and treatment of mental disorders by leveraging biological insights and developing innovative, mechanism-based treatment strategies unconstrained by current diagnostic boundaries. At its core, precision psychiatry aims to pinpoint the underlying neurobiological mechanisms responsible for the emergence and persistence of symptoms of mental health conditions. This approach strives to create diagnostic tools and therapies targeting these mechanisms, potentially addressing previously resistant aspects of mental health conditions by providing more precise symptom management and possibly altering the disease trajectory. Although still in its nascent stages, the realization of precision psychiatry will result in a more refined and biology-informed diagnostic system for mental disorders, requiring significant adaptations for clinicians, industry, patients and regulators. Identifying, validating and applying both fluid and functional biomarkers are critical steps in the development, testing and application of new precision psychiatry diagnostics and treatments. As part of the 2025 Precision Psychiatry Roadmap initiative meeting in Frankfurt, experts came together to present and discuss the current status of biomarker identification and validation, patient subtyping, and targeted interventions for stratified patient groups. This report features lecture summaries, meeting outcomes, and recommendations from both online and in-person audiences. In general, the recommendations emphasize standardization, collaboration, clinical implementation, digital innovation, long-term planning, and, importantly, patient engagement, as key priorities for advancing precision psychiatry. Despite existing challenges, there is strong optimism for the future of precision psychiatry, with continuous efforts to refine diagnostic tools and treatment strategies.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"105 ","pages":"Article 112762"},"PeriodicalIF":6.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145975227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging neurobiological targets in psychiatric treatment 精神病学治疗中新兴的神经生物学靶点

IF 6.7 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2026-04-01 Epub Date: 2026-01-27 DOI: 10.1016/j.euroneuro.2026.112767

Agampodi Ishan De Zoysa , Janani Govinnage , Frank Giorlando , Seetal Dodd , JC Narayanaswamy , Michael Berk

Despite significant advancements in psychopharmacology, there are inadequate treatment options for many psychiatric disorders, including major depressive disorder, bipolar disorder, schizophrenia, and anxiety disorders. This review explores emerging neurobiological targets beyond conventional monoaminergic approaches, focusing on sodium channels, Neuropeptide Y (NPY), Neurokinin 1 (NK1) receptors, P2 × 7 purinergic receptors, Sigma-1 receptors, and Orexin. Recent evidence suggests that sodium channel modulators, such as evenamide, may offer therapeutic benefits for treatment-resistant schizophrenia by stabilizing glutamatergic neurotransmission. NPY-based therapies have potential in stress-related disorders, foreshadowing rapid anxiolytic and antidepressant effects through modulation of the stress response. NK1 receptor antagonists, although inconsistent in mood disorders, show promise in addiction treatment by reducing substance cravings. The P2 × 7 receptor, a key regulator of neuroinflammation, has been implicated in mood disorders, and its pharmacological inhibition may provide neuroprotective benefits. Additionally, Sigma-1 receptor agonists, including Blarcamesine and Pridopidine, have shown neuroprotective and cognitive-enhancing properties, making them attractive candidates for psychiatric and neurodegenerative disorders. Orexin receptor antagonists, such as suvorexant and seltorexant, have potential in mood disorders and substance dependence, highlighting the broader therapeutic applications of targeting the orexinergic system. While these emerging therapeutic targets hold promise, challenges remain in translating preclinical findings into effective clinical applications. Large-scale, placebo-controlled trials are necessary to establish their efficacy and safety. The identification of biomarkers for patient stratification will be critical in the hitherto elusive goal of developing precision medicine approaches. Targeted pharmacological interventions offer a path toward more effective, well-tolerated, and potentially individualized treatment options for patients with severe mental illness.

尽管精神药理学取得了重大进展，但许多精神疾病的治疗选择仍然不足，包括重度抑郁症、双相情感障碍、精神分裂症和焦虑症。本文综述了传统单胺能途径之外的新兴神经生物学靶点，重点是钠通道、神经肽Y （NPY）、神经激肽1 （NK1）受体、P2 × 7嘌呤能受体、Sigma-1受体和食欲素。最近的证据表明，钠通道调节剂，如evenamide，可能通过稳定谷氨酸能神经传递，为治疗难治性精神分裂症提供治疗益处。基于npy的疗法在压力相关疾病中具有潜力，预示着通过调节应激反应来快速缓解焦虑和抗抑郁。NK1受体拮抗剂虽然在情绪障碍中不一致，但通过减少对物质的渴望，在成瘾治疗中显示出希望。P2 × 7受体是神经炎症的关键调节因子，与情绪障碍有关，其药理抑制可能具有神经保护作用。此外，Sigma-1受体激动剂，包括Blarcamesine和Pridopidine，已经显示出神经保护和认知增强的特性，使它们成为精神和神经退行性疾病的有吸引力的候选者。食欲素受体拮抗剂，如suvorexant和seltorexant，在情绪障碍和物质依赖中具有潜力，突出了针对食欲素能系统的更广泛的治疗应用。虽然这些新兴的治疗靶点有希望，但在将临床前发现转化为有效的临床应用方面仍然存在挑战。需要大规模的安慰剂对照试验来确定其有效性和安全性。识别患者分层的生物标志物对于迄今为止难以实现的发展精准医学方法的目标至关重要。有针对性的药物干预为严重精神疾病患者提供了一条更有效、耐受性良好、潜在的个性化治疗选择的途径。

{"title":"Emerging neurobiological targets in psychiatric treatment","authors":"Agampodi Ishan De Zoysa , Janani Govinnage , Frank Giorlando , Seetal Dodd , JC Narayanaswamy , Michael Berk","doi":"10.1016/j.euroneuro.2026.112767","DOIUrl":"10.1016/j.euroneuro.2026.112767","url":null,"abstract":"<div><div>Despite significant advancements in psychopharmacology, there are inadequate treatment options for many psychiatric disorders, including major depressive disorder, bipolar disorder, schizophrenia, and anxiety disorders. This review explores emerging neurobiological targets beyond conventional monoaminergic approaches, focusing on sodium channels, Neuropeptide Y (NPY), Neurokinin 1 (NK1) receptors, P2 × 7 purinergic receptors, Sigma-1 receptors, and Orexin. Recent evidence suggests that sodium channel modulators, such as evenamide, may offer therapeutic benefits for treatment-resistant schizophrenia by stabilizing glutamatergic neurotransmission. NPY-based therapies have potential in stress-related disorders, foreshadowing rapid anxiolytic and antidepressant effects through modulation of the stress response. NK1 receptor antagonists, although inconsistent in mood disorders, show promise in addiction treatment by reducing substance cravings. The P2 × 7 receptor, a key regulator of neuroinflammation, has been implicated in mood disorders, and its pharmacological inhibition may provide neuroprotective benefits. Additionally, Sigma-1 receptor agonists, including Blarcamesine and Pridopidine, have shown neuroprotective and cognitive-enhancing properties, making them attractive candidates for psychiatric and neurodegenerative disorders. Orexin receptor antagonists, such as suvorexant and seltorexant, have potential in mood disorders and substance dependence, highlighting the broader therapeutic applications of targeting the orexinergic system. While these emerging therapeutic targets hold promise, challenges remain in translating preclinical findings into effective clinical applications. Large-scale, placebo-controlled trials are necessary to establish their efficacy and safety. The identification of biomarkers for patient stratification will be critical in the hitherto elusive goal of developing precision medicine approaches. Targeted pharmacological interventions offer a path toward more effective, well-tolerated, and potentially individualized treatment options for patients with severe mental illness.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"105 ","pages":"Article 112767"},"PeriodicalIF":6.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146090563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epigenetic Clocks: An emerging role for Biomarkers of Aging in Psychiatry 表观遗传时钟：精神病学中衰老生物标志物的新角色

IF 6.7 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2026-04-01 Epub Date: 2026-01-07 DOI: 10.1016/j.euroneuro.2025.112749

Alba Navarro-Flores , Anthony S. Zannas

引用次数: 0

Antipsychotic plasma concentration as predictor of movement disorders and cardiometabolic side-effects: A comparison with prescription dose 抗精神病药血浆浓度作为运动障碍和心脏代谢副作用的预测因子：与处方剂量的比较

IF 6.7 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2026-04-01 Epub Date: 2026-01-22 DOI: 10.1016/j.euroneuro.2026.112769

Yinzhao Liu , Iris E Sommer , Georgios Schoretsanitis , Iris Hamers , Toon A W Scheurink , Marieke J H Begemann , Shiral S Gangadin , Nico J M van Beveren

The clinical evidence for antipsychotic (AP) therapeutic drug monitoring (TDM) in evaluating AP-related movement disorders and cardiometabolic side-effects remains inconsistent. This study evaluates how AP plasma concentrations associate with movement disorders and cardiometabolic side-effects over time, and compares its predictive value to prescription dose in first-episode psychosis (FEP) patients. We included 200 remitted FEP patients from the HAMLETT trial. AP plasma concentrations were standardized using robust z-scores to accommodate different AP types. The St. Hans Rating Scale and Barnes Akathisia Rating Scale assessed movement disorders. Cardiometabolic indices included body mass index, waist circumference, blood pressure, glucose, triglycerides, and cholesterol. We evaluated longitudinal associations between plasma concentrations, movement disorders and cardiometabolic side-effects using two-part and linear mixed-effects models, and compared its predictive value to prescription dose using Bayesian Information Criterion (ΔBIC). Over a median 6-month follow-up (range = 0–48), AP plasma concentrations were positively associated with odds for parkinsonism (OR = 1.81, 95 % CI 1.27, 2.57, p = 0.001). No associations were found with tardive dyskinesia, akathisia, tardive dystonia, or cardiometabolic indices. AP plasma concentrations predicted parkinsonism better than prescription dose (ΔBIC = -2.95), but showed lower predictive value for waist circumference (ΔBIC = 3.22), total cholesterol (ΔBIC = 3.70), low-density-lipoprotein cholesterol (ΔBIC = 2.14) and non-high-density-lipoprotein cholesterol (ΔBIC = 5.46). These findings suggest that in remitted FEP patients, AP TDM may be more useful than dose in evaluating parkinsonism, likely because plasma concentrations more closely reflect free drugs at striatal dopamine receptors, but it does not appear useful for cardiometabolic side-effects.

抗精神病（AP）治疗药物监测（TDM）在评估AP相关运动障碍和心脏代谢副作用方面的临床证据仍然不一致。本研究评估了AP血浆浓度随时间推移与运动障碍和心脏代谢副作用的关系，并将其与首发精神病（FEP）患者的处方剂量的预测价值进行了比较。我们纳入了来自HAMLETT试验的200例FEP患者。使用稳健的z分数对AP血浆浓度进行标准化，以适应不同的AP类型。圣汉斯评定量表和巴恩斯无运动障碍评定量表评估运动障碍。心脏代谢指标包括体重指数、腰围、血压、葡萄糖、甘油三酯和胆固醇。我们使用两部分和线性混合效应模型评估了血浆浓度、运动障碍和心脏代谢副作用之间的纵向关联，并使用贝叶斯信息标准（ΔBIC）将其预测值与处方剂量进行了比较。在中位6个月的随访（范围= 0-48）中，AP血浆浓度与帕金森病的几率呈正相关（OR = 1.81, 95% CI 1.27, 2.57, p = 0.001）。未发现与迟发性运动障碍、无运动障碍、迟发性肌张力障碍或心脏代谢指数相关。血浆AP浓度对帕金森病的预测效果优于处方剂量（ΔBIC = -2.95），但对腰围（ΔBIC = 3.22）、总胆固醇（ΔBIC = 3.70）、低密度脂蛋白胆固醇（ΔBIC = 2.14）和非高密度脂蛋白胆固醇（ΔBIC = 5.46）的预测效果较差。这些发现表明，在缓解的FEP患者中，AP TDM可能比剂量在评估帕金森病方面更有用，可能是因为血浆浓度更接近地反映纹状体多巴胺受体的游离药物，但它似乎对心脏代谢副作用没有帮助。

{"title":"Antipsychotic plasma concentration as predictor of movement disorders and cardiometabolic side-effects: A comparison with prescription dose","authors":"Yinzhao Liu , Iris E Sommer , Georgios Schoretsanitis , Iris Hamers , Toon A W Scheurink , Marieke J H Begemann , Shiral S Gangadin , Nico J M van Beveren","doi":"10.1016/j.euroneuro.2026.112769","DOIUrl":"10.1016/j.euroneuro.2026.112769","url":null,"abstract":"<div><div>The clinical evidence for antipsychotic (AP) therapeutic drug monitoring (TDM) in evaluating AP-related movement disorders and cardiometabolic side-effects remains inconsistent. This study evaluates how AP plasma concentrations associate with movement disorders and cardiometabolic side-effects over time, and compares its predictive value to prescription dose in first-episode psychosis (FEP) patients. We included 200 remitted FEP patients from the HAMLETT trial. AP plasma concentrations were standardized using robust z-scores to accommodate different AP types. The St. Hans Rating Scale and Barnes Akathisia Rating Scale assessed movement disorders. Cardiometabolic indices included body mass index, waist circumference, blood pressure, glucose, triglycerides, and cholesterol. We evaluated longitudinal associations between plasma concentrations, movement disorders and cardiometabolic side-effects using two-part and linear mixed-effects models, and compared its predictive value to prescription dose using Bayesian Information Criterion (ΔBIC). Over a median 6-month follow-up (range = 0–48), AP plasma concentrations were positively associated with odds for parkinsonism (OR = 1.81, 95 % CI 1.27, 2.57, <em>p</em> = 0.001). No associations were found with tardive dyskinesia, akathisia, tardive dystonia, or cardiometabolic indices. AP plasma concentrations predicted parkinsonism better than prescription dose (ΔBIC = -2.95), but showed lower predictive value for waist circumference (ΔBIC = 3.22), total cholesterol (ΔBIC = 3.70), low-density-lipoprotein cholesterol (ΔBIC = 2.14) and non-high-density-lipoprotein cholesterol (ΔBIC = 5.46). These findings suggest that in remitted FEP patients, AP TDM may be more useful than dose in evaluating parkinsonism, likely because plasma concentrations more closely reflect free drugs at striatal dopamine receptors, but it does not appear useful for cardiometabolic side-effects.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"105 ","pages":"Article 112769"},"PeriodicalIF":6.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146035529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to the letter regarding “Default mode network integrity across neuropsychiatric disorders and its relation to social dysfunction: A normative modelling approach” 对“神经精神疾病的默认模式网络完整性及其与社会功能障碍的关系：一种规范的建模方法”的回复

IF 6.7 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2026-04-01 Epub Date: 2026-01-15 DOI: 10.1016/j.euroneuro.2026.112764

Simon Braak , Martien J.H. Kas , Brenda W.J.H. Penninx

引用次数: 0

Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocols 弥合报告差距：ReSPCT指南在裸盖菇素临床试验方案中的应用

IF 6.7 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2026-04-01 Epub Date: 2026-01-16 DOI: 10.1016/j.euroneuro.2025.112746

Damian Swieczkowski , Aleksander Kwaśny , Krzysztof Sadko , Wiesław Jerzy Cubała

Psilocybin-assisted therapies are increasingly studied for Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD), and methodological rigor requires both pharmacological evaluation and consistent reporting of non-pharmacological variables that influence therapeutic outcomes. To address this need, the ReSPCT (Reporting of Setting in Psychedelic Clinical Trials) guidelines were recently introduced, providing a 30-item framework for standardized reporting of set and setting. This study aimed to evaluate how current psilocybin clinical trial protocols incorporate these elements and to identify domains requiring improvement. We systematically searched ClinicalTrials.gov and the EU Clinical Trials Information System (CTIS) for interventional psilocybin studies targeting MDD or TRD, including protocols listing depression as a primary condition. By June 21, 2025, 13 protocols (11 Phase II and 2 Phase III) met the inclusion criteria. Each protocol was assessed using the ReSPCT checklist, yielding a total of 390 item-level assessments rated on a four-point scale. Overall, 61 of 390 entries (15.6%) demonstrated full compliance, 252 (64.6%) partial compliance, and 77 (19.7%) provided no relevant information. Procedural elements, such as medical and experimental procedures (100% compliance), focus and main activities (92.3%), number of sessions (69.2%), and dosing regimens (53.8%), were consistently reported. In contrast, contextual and equity-related domains were markedly underreported: 84.6% of protocols lacked information on cultural competence and safety, 92.3% did not describe objects or decorations, and 84.6% failed to report access to nature. These findings indicate that while procedural safeguards are well documented, critical contextual and equity-relevant aspects remain insufficiently reported. Adopting ReSPCT guidelines may improve transparency and reproducibility.

对裸盖菇素辅助治疗重度抑郁症（MDD）和难治性抑郁症（TRD）的研究越来越多，方法的严密性要求药理学评估和影响治疗结果的非药理学变量的一致报告。为了满足这一需求，最近引入了《致幻剂临床试验环境报告》（ReSPCT）指南，为环境和环境的标准化报告提供了30个项目的框架。本研究旨在评估当前裸盖菇素临床试验方案如何纳入这些要素，并确定需要改进的领域。我们系统地检索了ClinicalTrials.gov和EU临床试验信息系统（CTIS），寻找针对重度抑郁症或TRD的裸盖菇素干预性研究，包括将抑郁症列为主要疾病的方案。截至2025年6月21日，13个方案（11个II期和2个III期）符合纳入标准。使用ReSPCT检查表对每个方案进行评估，共产生390个项目级评估，按4分制评分。总体而言，390个条目中有61个（15.6%）完全符合要求，252个（64.6%）部分符合要求，77个（19.7%）没有提供相关信息。程序要素，如医疗和实验程序（100%遵守）、重点和主要活动（92.3%）、疗程数（69.2%）和给药方案（53.8%），均得到一致报告。相比之下，上下文和公平相关的领域明显被低估：84.6%的协议缺乏文化能力和安全的信息，92.3%的协议没有描述物体或装饰，84.6%的协议没有报告对自然的获取。这些调查结果表明，虽然程序性保障有充分的文件记录，但关键的背景和与公平有关的方面仍然没有得到充分报告。采用尊重准则可以提高透明度和可重复性。

{"title":"Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocols","authors":"Damian Swieczkowski , Aleksander Kwaśny , Krzysztof Sadko , Wiesław Jerzy Cubała","doi":"10.1016/j.euroneuro.2025.112746","DOIUrl":"10.1016/j.euroneuro.2025.112746","url":null,"abstract":"<div><div>Psilocybin-assisted therapies are increasingly studied for Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD), and methodological rigor requires both pharmacological evaluation and consistent reporting of non-pharmacological variables that influence therapeutic outcomes. To address this need, the ReSPCT (Reporting of Setting in Psychedelic Clinical Trials) guidelines were recently introduced, providing a 30-item framework for standardized reporting of set and setting. This study aimed to evaluate how current psilocybin clinical trial protocols incorporate these elements and to identify domains requiring improvement. We systematically searched ClinicalTrials.gov and the EU Clinical Trials Information System (CTIS) for interventional psilocybin studies targeting MDD or TRD, including protocols listing depression as a primary condition. By June 21, 2025, 13 protocols (11 Phase II and 2 Phase III) met the inclusion criteria. Each protocol was assessed using the ReSPCT checklist, yielding a total of 390 item-level assessments rated on a four-point scale. Overall, 61 of 390 entries (15.6%) demonstrated full compliance, 252 (64.6%) partial compliance, and 77 (19.7%) provided no relevant information. Procedural elements, such as medical and experimental procedures (100% compliance), focus and main activities (92.3%), number of sessions (69.2%), and dosing regimens (53.8%), were consistently reported. In contrast, contextual and equity-related domains were markedly underreported: 84.6% of protocols lacked information on cultural competence and safety, 92.3% did not describe objects or decorations, and 84.6% failed to report access to nature. These findings indicate that while procedural safeguards are well documented, critical contextual and equity-relevant aspects remain insufficiently reported. Adopting ReSPCT guidelines may improve transparency and reproducibility.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"105 ","pages":"Article 112746"},"PeriodicalIF":6.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145975226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Child and maternal hair oxytocin: A novel biomarker of dyadic emotional availability 儿童和母亲的头发催产素：一种新的二元情绪可用性生物标志物

IF 6.7 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2026-04-01 Epub Date: 2026-01-16 DOI: 10.1016/j.euroneuro.2026.112763

Liat Zelikovich Moyal, Tamar Kadosh-Laor, Laure D. Sultan, Liat Israeli-Ran, Florina Uzefovsky

引用次数: 0

Gene-environment interactions and white matter integrity in mood disorders: Further directions 情绪障碍中的基因-环境相互作用和白质完整性：进一步研究方向。

IF 6.7 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2026-04-01 Epub Date: 2026-01-17 DOI: 10.1016/j.euroneuro.2026.112770

Yanlong Yao, Xu Fan

引用次数: 0

Long-term adjunctive lumateperone 42 mg treatment in major depressive disorder: Results from a 6-month open-label extension study. 长期辅助lumateperone 42 mg治疗重度抑郁症：一项为期6个月的开放标签扩展研究结果

IF 6.7 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2026-03-24 DOI: 10.1016/j.euroneuro.2026.112786

Suresh Durgam, Willie R Earley, Susan G Kozauer, Changzheng Chen, Hassan Lakkis, Andrew J Cutler

This Phase 3 open-label extension study (NCT05061719) investigated long-term safety of lumateperone 42mg (simultaneous modulator of serotonin, dopamine, and glutamate neurotransmission) adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) with inadequate ADT response. Eligible adults (18-65years) completed 6-week double-blind treatment (NCT04985942; NCT05061706) and had DSM-5-defined MDD with inadequate response to 1-2 ADTs in the current depressive episode, Montgomery-Åsberg Depression Rating Scale (MADRS) Total score ≥24, and Clinical Global Impression-Severity (CGI-S) score ≥4 at lead-in study entry. Patients received 26-week, open-label, oral lumateperone 42mg+ADT once-daily. The primary endpoint was safety/tolerability, assessed by adverse events (AEs), vital signs, and laboratory parameters. The secondary endpoint was efficacy, assessed by MADRS Total score and CGI-S score changes from double-blind baseline to open-label Week 26. Of 809 patients treated, 84.5% completed open-label treatment; 67.7% experienced ≥1 treatment-emergent AE (TEAE). Most common TEAEs (≥5%) were headache (16.6%), dizziness (10.6%), dry mouth (8.0%), nausea (7.7%), somnolence (7.2%), diarrhea (6.2%), and nasopharyngitis (5.2%). The majority (98.9%) of TEAEs were mild-to-moderate severity. Rate of extrapyramidal symptom (EPS)-related TEAEs per broad standardized MedDRA query was low (3.8%). No notable changes in EPS scales, body morphology, or cardiometabolic parameters occurred from double-blind baseline to end of open-label treatment. No emergence of suicidal behavior occurred during treatment. Symptoms of depression improved with lumateperone+ADT from double-blind baseline to open-label Week 26 (mean change: MADRS Total score=-22.9, P<.0001; CGI-S score=-2.7, P<.0001). Overall, lumateperone 42mg+ADT was safe and effective during 26-week treatment in patients with MDD with inadequate ADT response.

这项3期开放标签扩展研究（NCT05061719）调查了lumateperone 42mg（血清素、多巴胺和谷氨酸神经传递的同步调节剂）辅助抗抑郁治疗（ADT）对ADT反应不足的重度抑郁症（MDD）患者的长期安全性。符合条件的成人（18-65岁）完成了为期6周的双盲治疗（NCT04985942; NCT05061706），并患有dsm -5定义的重度抑郁症，当前抑郁发作时对1-2次ADTs反应不足，Montgomery-Åsberg抑郁评定量表（MADRS）总分≥24分，临床总体印象严重程度（CGI-S）评分≥4分。患者接受26周，开放标签，口服lumateperone 42mg+ADT，每日一次。主要终点是安全性/耐受性，通过不良事件（ae）、生命体征和实验室参数进行评估。次要终点是疗效，通过MADRS总分和CGI-S评分从双盲基线到开放标签第26周的变化来评估。在接受治疗的809名患者中，84.5%完成了开放标签治疗；67.7%经历≥1次治疗后突发AE （TEAE）。最常见的teae（≥5%）为头痛（16.6%）、头晕（10.6%）、口干（8.0%）、恶心（7.7%）、嗜睡（7.2%）、腹泻（6.2%）和鼻咽炎（5.2%）。大多数teae（98.9%）的严重程度为轻至中度。每个广泛标准化MedDRA查询中锥体外系症状（EPS）相关teae的比率较低（3.8%）。从双盲基线到开放标签治疗结束，EPS量表、身体形态或心脏代谢参数均未发生显著变化。治疗期间未出现自杀行为。从双盲基线到开放标签第26周，lumateperone+ADT治疗抑郁症状得到改善（平均变化：MADRS）

{"title":"Long-term adjunctive lumateperone 42 mg treatment in major depressive disorder: Results from a 6-month open-label extension study.","authors":"Suresh Durgam, Willie R Earley, Susan G Kozauer, Changzheng Chen, Hassan Lakkis, Andrew J Cutler","doi":"10.1016/j.euroneuro.2026.112786","DOIUrl":"https://doi.org/10.1016/j.euroneuro.2026.112786","url":null,"abstract":"<p><p>This Phase 3 open-label extension study (NCT05061719) investigated long-term safety of lumateperone 42mg (simultaneous modulator of serotonin, dopamine, and glutamate neurotransmission) adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) with inadequate ADT response. Eligible adults (18-65years) completed 6-week double-blind treatment (NCT04985942; NCT05061706) and had DSM-5-defined MDD with inadequate response to 1-2 ADTs in the current depressive episode, Montgomery-Åsberg Depression Rating Scale (MADRS) Total score ≥24, and Clinical Global Impression-Severity (CGI-S) score ≥4 at lead-in study entry. Patients received 26-week, open-label, oral lumateperone 42mg+ADT once-daily. The primary endpoint was safety/tolerability, assessed by adverse events (AEs), vital signs, and laboratory parameters. The secondary endpoint was efficacy, assessed by MADRS Total score and CGI-S score changes from double-blind baseline to open-label Week 26. Of 809 patients treated, 84.5% completed open-label treatment; 67.7% experienced ≥1 treatment-emergent AE (TEAE). Most common TEAEs (≥5%) were headache (16.6%), dizziness (10.6%), dry mouth (8.0%), nausea (7.7%), somnolence (7.2%), diarrhea (6.2%), and nasopharyngitis (5.2%). The majority (98.9%) of TEAEs were mild-to-moderate severity. Rate of extrapyramidal symptom (EPS)-related TEAEs per broad standardized MedDRA query was low (3.8%). No notable changes in EPS scales, body morphology, or cardiometabolic parameters occurred from double-blind baseline to end of open-label treatment. No emergence of suicidal behavior occurred during treatment. Symptoms of depression improved with lumateperone+ADT from double-blind baseline to open-label Week 26 (mean change: MADRS Total score=-22.9, P<.0001; CGI-S score=-2.7, P<.0001). Overall, lumateperone 42mg+ADT was safe and effective during 26-week treatment in patients with MDD with inadequate ADT response.</p>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"108 ","pages":"112786"},"PeriodicalIF":6.7,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147510394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revisiting the earlier, pre-CHR-P prodrome of psychotic illness: a desideratum for advancing early intervention? 重新审视早期的，chrp前精神疾病的前驱症状：推进早期干预的愿望？

IF 6.7 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2026-03-23 DOI: 10.1016/j.euroneuro.2026.112825

Nnamdi Nkire, Anthony Kinsella, Vincent Russell, John L Waddington

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

European Neuropsychopharmacology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀